C-Peptide Blood Test - Insulin Production & Diabetes Assessment guide

What is C-Peptide and why is it important?

The C-peptide test is primarily used to evaluate hypoglycemia, helping distinguish between endogenous insulin production (e.g., from insulin-secreting tumors) and exogenous insulin administration. It is also valuable for assessing residual beta-cell function in individuals with diabetes, especially when insulin antibodies interfere with direct insulin assays. High C-peptide levels with low plasma glucose can support the diagnosis of an islet cell tumor.

When to consider C-Peptide?

When to Consider a C-Peptide Test

If you are experiencing recurrent episodes of unexplained low blood sugar (hypoglycemia) symptoms.
To help your doctor assess the function of your insulin-producing beta cells, especially if you have diabetes.
As part of the diagnostic process for a suspected insulin-producing tumor (insulinoma).
If your healthcare provider needs to differentiate between insulin produced by your body and insulin that has been injected.

Who benefits from C-Peptide?

Who Should Consider This Test?

Individuals experiencing symptoms of low blood sugar (hypoglycemia), such as dizziness, confusion, shakiness, or unexplained fatigue.
People with diabetes, particularly those on insulin therapy, to evaluate their body's remaining natural insulin production.
Those suspected of having an insulin-producing tumor (insulinoma) or other conditions affecting insulin secretion.
Patients whose healthcare providers need to distinguish between naturally produced insulin and externally administered insulin, such as in cases of factitious hypoglycemia or to monitor pancreatic function.

When is the C-Peptide used?

Common Diagnostic Applications

The C-peptide test is a vital tool for diagnosing and managing several conditions related to insulin production and glucose regulation:

Insulinoma: It is crucial for diagnosing insulinomas, which are rare tumors of the pancreas that produce excessive insulin. In patients with suspected insulinoma, C-peptide levels will be inappropriately high during episodes of hypoglycemia, indicating endogenous overproduction of insulin.
Factitious Hypoglycemia: This test helps differentiate between naturally occurring hypoglycemia and hypoglycemia caused by the surreptitious administration of exogenous insulin. In factitious hypoglycemia due to insulin injection, C-peptide levels will be suppressed, while exogenous insulin levels will be elevated.
Type 1 and Type 2 Diabetes Assessment: For individuals with diabetes, C-peptide levels provide insight into residual beta-cell function. In Type 1 diabetes, C-peptide levels are typically very low or undetectable, reflecting minimal to no endogenous insulin production. In contrast, patients with Type 2 diabetes often have normal to elevated C-peptide levels, especially in the early stages, indicating ongoing but often insufficient insulin production or insulin resistance.
Monitoring Pancreatic Islet Cell Function: It can be used to monitor the effectiveness of treatments aimed at preserving or restoring pancreatic beta-cell function, or to assess the success of pancreatic or islet cell transplantation.

Important Considerations

Results from a C-Peptide test should always be interpreted by a qualified healthcare provider in the context of your complete medical history, current symptoms, and other diagnostic test results. Factors such as kidney function or the use of certain medications can significantly influence C-Peptide levels and must be taken into account for accurate interpretation.